Literature DB >> 21403397

CD4+ T cells from elite controllers resist HIV-1 infection by selective upregulation of p21.

Huabiao Chen1, Chun Li, Jinghe Huang, Thai Cung, Katherine Seiss, Jill Beamon, Mary F Carrington, Lindsay C Porter, Patrick S Burke, Yue Yang, Bethany J Ryan, Ruiwu Liu, Robert H Weiss, Florencia Pereyra, William D Cress, Abraham L Brass, Eric S Rosenberg, Bruce D Walker, Xu G Yu, Mathias Lichterfeld.   

Abstract

Elite controllers represent a unique group of HIV-1-infected persons with undetectable HIV-1 replication in the absence of antiretroviral therapy. However, the mechanisms contributing to effective viral immune defense in these patients remain unclear. Here, we show that compared with HIV-1 progressors and HIV-1-negative persons, CD4+ T cells from elite controllers are less susceptible to HIV-1 infection. This partial resistance to HIV-1 infection involved less effective reverse transcription and mRNA transcription from proviral DNA and was associated with strong and selective upregulation of the cyclin-dependent kinase inhibitor p21 (also known as cip-1 and waf-1). Experimental blockade of p21 in CD4+ T cells from elite controllers resulted in a marked increase of viral reverse transcripts and mRNA production and led to higher enzymatic activities of cyclin-dependent kinase 9 (CDK9), which serves as a transcriptional coactivator of HIV-1 gene expression. This suggests that p21 acts as a barrier against HIV-1 infection in CD4+ T cells from elite controllers by inhibiting a cyclin-dependent kinase required for effective HIV-1 replication. These data demonstrate a mechanism of host resistance to HIV-1 in elite controllers and may open novel perspectives for clinical strategies to prevent or treat HIV-1 infection.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21403397      PMCID: PMC3069774          DOI: 10.1172/JCI44539

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  45 in total

1.  The cell cycle inhibitor p21 controls T-cell proliferation and sex-linked lupus development.

Authors:  D Balomenos; J Martín-Caballero; M I García; I Prieto; J M Flores; M Serrano; C Martínez-A
Journal:  Nat Med       Date:  2000-02       Impact factor: 53.440

Review 2.  Cyclin-dependent kinases as cellular targets for antiviral drugs.

Authors:  Luis M Schang
Journal:  J Antimicrob Chemother       Date:  2002-12       Impact factor: 5.790

3.  HIV-specific CD8+ T cell proliferation is coupled to perforin expression and is maintained in nonprogressors.

Authors:  Stephen A Migueles; Alisha C Laborico; W Lesley Shupert; M Shirin Sabbaghian; Ronald Rabin; Claire W Hallahan; Debbie Van Baarle; Stefan Kostense; Frank Miedema; Mary McLaughlin; Linda Ehler; Julia Metcalf; Shuying Liu; Mark Connors
Journal:  Nat Immunol       Date:  2002-10-07       Impact factor: 25.606

4.  Isolation and functional characterization of P-TEFb-associated factors that control general and HIV-1 transcriptional elongation.

Authors:  Ruichuan Chen; Min Liu; Kai Zhang; Qiang Zhou
Journal:  Methods       Date:  2010-04-10       Impact factor: 3.608

5.  Inhibition of human immunodeficiency virus type 1 transcription by chemical cyclin-dependent kinase inhibitors.

Authors:  D Wang; C de la Fuente; L Deng; L Wang; I Zilberman; C Eadie; M Healey; D Stein; T Denny; L E Harrison; L Meijer; F Kashanchi
Journal:  J Virol       Date:  2001-08       Impact factor: 5.103

6.  P-TEFb kinase is required for HIV Tat transcriptional activation in vivo and in vitro.

Authors:  H S Mancebo; G Lee; J Flygare; J Tomassini; P Luu; Y Zhu; J Peng; C Blau; D Hazuda; D Price; O Flores
Journal:  Genes Dev       Date:  1997-10-15       Impact factor: 11.361

7.  Human immunodeficiency virus type 1 vectors efficiently transduce human hematopoietic stem cells.

Authors:  R E Sutton; H T Wu; R Rigg; E Böhnlein; P O Brown
Journal:  J Virol       Date:  1998-07       Impact factor: 5.103

Review 8.  The influence of HLA genotype on AIDS.

Authors:  Mary Carrington; Stephen J O'Brien
Journal:  Annu Rev Med       Date:  2001-12-03       Impact factor: 13.739

9.  Cytokine signals are sufficient for HIV-1 infection of resting human T lymphocytes.

Authors:  D Unutmaz; V N KewalRamani; S Marmon; D R Littman
Journal:  J Exp Med       Date:  1999-06-07       Impact factor: 14.307

10.  Loss of HIV-1-specific CD8+ T cell proliferation after acute HIV-1 infection and restoration by vaccine-induced HIV-1-specific CD4+ T cells.

Authors:  Mathias Lichterfeld; Daniel E Kaufmann; Xu G Yu; Stanley K Mui; Marylyn M Addo; Mary N Johnston; Daniel Cohen; Gregory K Robbins; Eunice Pae; Galit Alter; Alysse Wurcel; David Stone; Eric S Rosenberg; Bruce D Walker; Marcus Altfeld
Journal:  J Exp Med       Date:  2004-09-20       Impact factor: 14.307

View more
  105 in total

1.  Comprehensive analysis of unique cases with extraordinary control over HIV replication.

Authors:  Daniel Mendoza; Sarah A Johnson; Bennett A Peterson; Ven Natarajan; Maria Salgado; Robin L Dewar; Peter D Burbelo; Nicole A Doria-Rose; Erin H Graf; Jamieson H Greenwald; Jessica N Hodge; William L Thompson; Nancy A Cogliano; Cheryl L Chairez; Catherine A Rehm; Sara Jones; Claire W Hallahan; Joseph A Kovacs; Irini Sereti; Omar Sued; Sheila A Peel; Robert J O'Connell; Una O'Doherty; Tae-Wook Chun; Mark Connors; Stephen A Migueles
Journal:  Blood       Date:  2012-04-05       Impact factor: 22.113

2.  Elite controllers with low to absent effector CD8+ T cell responses maintain highly functional, broadly directed central memory responses.

Authors:  Zaza M Ndhlovu; Jacqueline Proudfoot; Kevin Cesa; Donna Marie Alvino; Ashley McMullen; Seanna Vine; Eleni Stampouloglou; Alicja Piechocka-Trocha; Bruce D Walker; Florencia Pereyra
Journal:  J Virol       Date:  2012-04-18       Impact factor: 5.103

3.  Phenyl-1-Pyridin-2yl-ethanone-based iron chelators increase IκB-α expression, modulate CDK2 and CDK9 activities, and inhibit HIV-1 transcription.

Authors:  Namita Kumari; Sergey Iordanskiy; Dmytro Kovalskyy; Denitra Breuer; Xiaomei Niu; Xionghao Lin; Min Xu; Konstantin Gavrilenko; Fatah Kashanchi; Subhash Dhawan; Sergei Nekhai
Journal:  Antimicrob Agents Chemother       Date:  2014-08-25       Impact factor: 5.191

Review 4.  Unravelling the mechanisms of durable control of HIV-1.

Authors:  Bruce D Walker; Xu G Yu
Journal:  Nat Rev Immunol       Date:  2013-07       Impact factor: 53.106

5.  Both HLA-B*57 and plasma HIV RNA levels contribute to the HIV-specific CD8+ T cell response in HIV controllers.

Authors:  Camille Lécuroux; Asier Sáez-Cirión; Isabelle Girault; Pierre Versmisse; Faroudy Boufassa; Véronique Avettand-Fenoël; Christine Rouzioux; Laurence Meyer; Gianfranco Pancino; Olivier Lambotte; Martine Sinet; Alain Venet
Journal:  J Virol       Date:  2013-10-16       Impact factor: 5.103

6.  p21-mediated RNR2 repression restricts HIV-1 replication in macrophages by inhibiting dNTP biosynthesis pathway.

Authors:  Awatef Allouch; Annie David; Sarah M Amie; Hichem Lahouassa; Loïc Chartier; Florence Margottin-Goguet; Françoise Barré-Sinoussi; Baek Kim; Asier Sáez-Cirión; Gianfranco Pancino
Journal:  Proc Natl Acad Sci U S A       Date:  2013-09-30       Impact factor: 11.205

7.  Impact of protective killer inhibitory receptor/human leukocyte antigen genotypes on natural killer cell and T-cell function in HIV-1-infected controllers.

Authors:  Costin Tomescu; Fuh-Mei Duh; Rebecca Hoh; Anne Viviani; Kara Harvill; Maureen P Martin; Mary Carrington; Steven G Deeks; Luis J Montaner
Journal:  AIDS       Date:  2012-09-24       Impact factor: 4.177

8.  Inhibition of HIV-1 integration in ex vivo-infected CD4 T cells from elite controllers.

Authors:  Maria J Buzon; Katherine Seiss; Robert Weiss; Abraham L Brass; Eric S Rosenberg; Florencia Pereyra; Xu G Yu; Mathias Lichterfeld
Journal:  J Virol       Date:  2011-07-06       Impact factor: 5.103

9.  Histone deacetylase inhibitors induce complex host responses that contribute to differential potencies of these compounds in HIV reactivation.

Authors:  Nadejda Beliakova-Bethell; Amey Mukim; Cory H White; Savitha Deshmukh; Hosiana Abewe; Douglas D Richman; Celsa A Spina
Journal:  J Biol Chem       Date:  2019-02-11       Impact factor: 5.157

10.  A novel p21 attenuator which is structurally related to sorafenib.

Authors:  Hiromi I Wettersten; Sung Hee Hwang; Cuiwen Li; Eunice Y Shiu; Aaron T Wecksler; Bruce D Hammock; Robert H Weiss
Journal:  Cancer Biol Ther       Date:  2013-01-08       Impact factor: 4.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.